Cell Surface Receptors Ly-9 and CD84 Recruit the X-linked Lymphoproliferative Disease Gene Product SAP
Overview
Affiliations
X-linked lymphoproliferative disease (XLP) is a rare immune disorder commonly triggered by infection with Epstein-Barr virus. Major disease manifestations include fatal acute infectious mononucleosis, B-cell lymphoma, and progressive dys-gammaglobulinemia. SAP/SH2D1A, the product of the gene mutated in XLP, is a small protein that comprises a single SH2 domain and a short tail of 26 amino acids. SAP binds to a specific motif in the cytoplasmic tails of the cell surface receptors SLAM and 2B4, where it blocks recruitment of the phosphatase SHP-2. Here it is reported that Ly-9 and CD84, 2 related glycoproteins differentially expressed on hematopoietic cells, also recruit SAP. Interactions between SAP and Ly-9 or CD84 were analyzed using a novel yeast 2-hybrid system, by COS cell transfections and in lymphoid cells. Recruitment of SAP is most efficient when the specific tyrosine residues in the cytoplasmic tails of Ly-9 or CD84 are phosphorylated. It is concluded that in activated T cells, the SAP protein binds to and regulates signal transduction events initiated through the engagement of SLAM, 2B4, CD84, and Ly-9. This suggests that combinations of dysfunctional signaling pathways initiated by these 4 cell surface receptors may cause the complex phenotypes of XLP. (Blood. 2001;97:3867-3874)
Song Y, Zhang Y, Wang Z, Lin Y, Cao X, Han X Oncogene. 2024; 43(36):2737-2749.
PMID: 39112517 DOI: 10.1038/s41388-024-03118-w.
SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy.
Farhangnia P, Ghomi S, Mollazadehghomi S, Nickho H, Akbarpour M, Delbandi A Front Immunol. 2023; 14:1174138.
PMID: 37251372 PMC: 10213746. DOI: 10.3389/fimmu.2023.1174138.
Are Viral Infections Key Inducers of Autoimmune Diseases? Focus on Epstein-Barr Virus.
Takei M, Kitamura N, Nagasawa Y, Tsuzuki H, Iwata M, Nagatsuka Y Viruses. 2022; 14(9).
PMID: 36146707 PMC: 9506567. DOI: 10.3390/v14091900.
CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma.
Roncador G, Punet-Ortiz J, Maestre L, Rodriguez-Lobato L, Jimenez S, Reyes-Garcia A Cancers (Basel). 2022; 14(9).
PMID: 35565280 PMC: 9101303. DOI: 10.3390/cancers14092154.
Immune Checkpoint Receptors Signaling in T Cells.
Baldanzi G Int J Mol Sci. 2022; 23(7).
PMID: 35408889 PMC: 8999077. DOI: 10.3390/ijms23073529.